Medi-Green, a wholly-owned subsidiary of Beleave (BE.CN) (BLEVF) (“Beleave” or the “Company“) is excited to invite the community to the grand opening event of its new clinic in London, Ontario this Friday, February 15, 2019.
“We are very excited to expand our Medi-Green family into the London region and continue to provide a comforting and encouraging environment for patients seeking medical cannabis as a form of treatment,” said Ashleigh Koeslag, Operations Manager.
During the event, staff from Medi-Green will be present to answer questions and share information about cannabis and the clinic’s services with attendees.
“Every Medi-Green is there to help individuals learn about cannabis and understand their options in a professional and safe space with an open-door policy,” said Keely Yuzpe, London Clinic Manager. “Not only are we here to help match questions with answers, but we’re excited to become an active part of the community. By supporting causes that are important to London residents, and getting involved with local business initiatives, we feel we’re well on our way and can’t wait to meet our neighbours.”
About the Grand Opening:
- Location: 211 Dundas Street, London, Ontario
- Date: February 15, 2018
- Time: 5 p.m. – 8 p.m. Eastern Time
- Come early! Don’t miss out on the door prizes and giveaways
- Light refreshments will be served
Background Information About Medi-Green:
- Assists in the education and access of safe medical cannabis through consultation, education and ongoing support
- Walks you through the entire process – from the initial application to aftercare
- Connects you with a doctor who specializes in medical cannabis treatment
- Patient Service Representatives are available to discuss your needs to assist with strain selections
- Pairs you with the right licensed producer to ensure you have the product quality, diversity and price point that fits your needs
- Helps you place your first order with your producer
- Assists you in choosing, purchasing and learning how to use cannabis equipment
ABOUT BELEAVE INC.
Beleave is a vertically-integrated, ISO certified, Canadian cannabis company headquartered in Oakville, Ontario, that cultivates high-quality cannabis flower, oil and extracts.
Beleave is fully-licenced to cultivate and sell medical and recreational cannabis and cannabis oil. Beleave is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives. Beleave is developing new product lines, including cannabis-infused powder and sugar products for 2019 as the recreational market is expected to allow for food and beverage-based cannabis products.
Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Through its majority ownership of Procannmed S.A.S., Beleave is fully licensed to cultivate, produce, and extract medical cannabis in Colombia to capitalize on exports and the expanding Latin American market. In a strategic initiative to penetrate the European medical market, the Company has partnered with Canymed GmbH to supply the German market with medical cannabis.
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.